Sampurna Chatterjee
Sampurna Chatterjee
I am currently leading multiple projects that aim to characterize and reprogram the abnormal tumor microenvironment in brain cancers ranging from devastating pediatric medulloblastoma and aggressive glioblastoma to develop novel therapeutics. My findings will help identify therapeutic biomarkers initiating rapid clinical translation.
Learn more by visiting my LinkedIn page.
https://www.linkedin.com/in/sampurna-chatterjee/
Publications
HideAuthor Correction: Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin.
Nat Biomed Eng. 2020;4(12):1222 - PMID: 33235308 - PMCID: PMC8328147 - DOI: 10.1038/s41551-020-00664-y
Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin.
Nat Biomed Eng. 2020;4(8):801-813 - PMID: 32572196 - PMCID: PMC8310386 - DOI: 10.1038/s41551-020-0569-y
A cerebellar window for intravital imaging of normal and disease states in mice.
Nat Protoc. 2017;12(11):2251-2262 - PMID: 28981123 - PMCID: PMC5918134 - DOI: 10.1038/nprot.2017.101
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Proc Natl Acad Sci U S A. 2016;113(16):4470-5 - PMID: 27044097 - PMCID: PMC4843449 - DOI: 10.1073/pnas.1525349113